A Study of LY2409021 in Patients With Type 2 Diabetes

Summary

LY2409021 is being evaluated for possible treatment in type 2 diabetes. This study is designed to compare LY2409021 given alone or given in combination with metformin against placebo the change in hemoglobin A1c after a 24-week treatment period.

Timeline

Start

2011-01

Primary completion

2012-02

Completion

2012-03

Outcome

Met primary endpoint

registry Placebo vs 10 mg LY2409021; p <0.001; Least Squares Mean Difference -0.62 (90% CI -0.90 to -0.34); Mixed Models Analysis NCT01241448 ↗

registry Placebo vs 20 mg LY2409021; p <0.01; Least Squares Mean Difference -0.77 (90% CI -1.05 to -0.48); Mixed Models Analysis NCT01241448 ↗

Publications

• Tan AYF, Schneck K, Garhyan P, Chan ECY, Tham LS. Evaluation of Four Semi-Mechanistic Models for Predicting Glycemic Control With a Glucagon Receptor Antagonist in People With Type 2 Diabetes. CPT Pharmacometrics Syst Pharmacol. 2025 Aug;14(8):1381-1390. doi: 10.1002/psp4.70058. Epub 2025 Jun 17.
• Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care. 2016 Jul;39(7):1241-9. doi: 10.2337/dc15-1643. Epub 2015 Dec 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADOMEGLIVANT	Small molecule	2.5 mg	Oral
Subject	ADOMEGLIVANT	Small molecule	10 mg	Oral
Subject	ADOMEGLIVANT	Small molecule	20 mg	Oral

Indications